SPATS2L and glioblastoma: We found that, compared with grade II–III glioma (LGG), the expression levels of SPATS2L were higher in GBM patients in the GSE4412, GSE16011, GSE43378, GSE83294, TCGA, and CGGA datasets (Figure 6C).